Daughter of Lake Wylie couple makes ‘Time 100’ list of influential people

relder@newsobserver.comMay 7, 2013 

— The daughter of a Lake Wylie couple has been named one of the 100 most influential people in the world by Time magazine.

Duke University oncologist Kimberly Blackwell – whose parents Ed and Carol Blackwell live in River Hills – has been a lead researcher on treatments targeting a protein found in a type of aggressive breast cancer.

The treatments she has helped develop are dubbed the “smart bombs” of oncology because they pair tumor-specific antibodies with chemotherapy drugs to target cancer cells with fewer unwanted side effects.

Blackwell says that when she got the news that she had been nominated to the annual list she was afraid to tell anyone.

“I got an email saying, ‘Congratulations, you’ve been nominated. We’d like you to come to New York for a gala,’” said Blackwell, 44. “It seemed so nonchalant, I thought it might be fake.”

Since then, an elaborate invitation arrived in the mail and the honor of appearing as one of the elite 100 in the April 29 edition of the magazine has registered with Blackwell, who has successfully led two cancer-fighting drugs through the arduous Federal Drug Administration approval process.

“It’s really recognition for me and for Duke and for all the women who participated in the drug trials and waited to get the treatments approved,” she said.

Her nomination as one of the Pioneers listed among the Time 100 – the other categories are Titans, Icons and Leaders – was submitted by Sherry Lansing, former chairman of Paramount Pictures and co-founder of the fundraising organization Stand Up to Cancer.

“The brilliant work of Kimberly and scientists like her gives us real hope that we may, at last, be turning the corner in the fight against cancer,” Lansing wrote.

Medicine is a theme in Blackwell’s family.

Her father, Ed Blackwell, now retired , spent years in the pharmaceutical business, which meant extensive traveling. Her sister, Kristin Robinson, is a nurse anesthetist living in Lake Wylie.

“I feel like the black sheep of the family,” says mom Carol Blackwell, a former Real Estate broker. “They sometimes get to talking about medicine, and I just sit there and say, OK.”

Both parents agree their daughters took more steering than pulling. Like when Kimberly considered veterinary medicine and Carol lined up a summer job with a vet, or when Kristin had to choose between medical training and business.

“They were always seekers,” Carol Blackwell said. “They always wanted to know the answers.”

Kimberly Blackwell grew up in Colorado with a love of horses and attended Duke as an undergraduate with an eye toward becoming a veterinarian – until a cell biology class “changed my world.”

She also credits a work-study experience assisting women through a National Cancer Institute telephone hot line.

“That’s how I found out how much cancer affects people’s lives,” she said. “I went off to med school knowing I wanted to be a breast cancer doctor.”

Blackwell graduated from Mayo Medical School in Minnesota in 1994 and returned to Duke for residency and fellowship work. Now a professor of medicine at Duke, Blackwell also has been listed by U.S. News and World Report as among the nation’s top 1 percent of physicians in breast oncology.

She considers her work a mission “to take care of women facing cancer.”

In February, a drug called T-DM1 that she helped develop and is now marketed as Kadcyla won FDA approval. The groundbreaking treatment pairs a strong chemotherapy drug with a “targeted” drug that delivers cancer treatment directly to the affected cells, sparing healthy ones.

In trials, T-DM1 was shown to be more effective at slowing or stopping the growth of breast cancer cells and creating fewer side effects than traditional treatments, Blackwell said.

She said she has been a critic of the FDA approval process because of the time it takes to get new medications on the market.

“We as a community need to think about how we can accelerate the development of these medicines,” she said.

And she has a special appreciation for drug trial participants.

“Imagine how brave you have to be to be involved in a clinical trial,” Blackwell said. “Facing cancer, every decision you make has a significant impact on your life.”

The clinical trial that led to the smart-bomb drug ran from 2009 to 2011, she said, and the results were published in the New England Journal of Medicine.

Blackwell said seeing her picture in Time is sure to raise her status with her two sons, Owen, 10, and Mason, 8.

“They finally realize what I do is really important,” she said.

John Marks of the Lake Wylie Pilot contributed.

The Herald is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service